Helicobacter pylori and peptic ulcer disease

M. Feldman, W. L. Peterson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Medical therapy for duodenal or gastric ulcer disease has traditionally involved gastric acid anti-secretory therapy for 4 to 8 weeks to promote initial healing and indefinitely to prevent recurrences of ulcer. The discovery of Helicobacter pylori in most patients with peptic ulcer disease has led to a change in this approach. Therapy designed to eradicate H pylori may facilitate ulcer healing with acid antisecretory agents and, more important, may greatly reduce the incidence of ulcer recurrence, obviating the need for maintenance antisecretory therapy. Regimens designed to eradicate H pylori are difficult to comply with, however, and are associated with adverse effects in some patients. In this article we review the diagnosis and treatment of H pylori infection in patients with peptic ulcer disease and make recommendations regarding the use of conventional ulcer therapies and therapies designed to eradicate H pylori.

Original languageEnglish (US)
Pages (from-to)555-559
Number of pages5
JournalWestern Journal of Medicine
Volume159
Issue number5
StatePublished - 1993

Fingerprint

Peptic Ulcer
Helicobacter pylori
Pylorus
Ulcer
Therapeutics
Stomach Diseases
Recurrence
Gastric Acid
Stomach Ulcer
Duodenal Ulcer
Maintenance
Acids
Incidence
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feldman, M., & Peterson, W. L. (1993). Helicobacter pylori and peptic ulcer disease. Western Journal of Medicine, 159(5), 555-559.

Helicobacter pylori and peptic ulcer disease. / Feldman, M.; Peterson, W. L.

In: Western Journal of Medicine, Vol. 159, No. 5, 1993, p. 555-559.

Research output: Contribution to journalArticle

Feldman, M & Peterson, WL 1993, 'Helicobacter pylori and peptic ulcer disease', Western Journal of Medicine, vol. 159, no. 5, pp. 555-559.
Feldman M, Peterson WL. Helicobacter pylori and peptic ulcer disease. Western Journal of Medicine. 1993;159(5):555-559.
Feldman, M. ; Peterson, W. L. / Helicobacter pylori and peptic ulcer disease. In: Western Journal of Medicine. 1993 ; Vol. 159, No. 5. pp. 555-559.
@article{824ea3c21c9c423bb9fbb7dbc45eb47c,
title = "Helicobacter pylori and peptic ulcer disease",
abstract = "Medical therapy for duodenal or gastric ulcer disease has traditionally involved gastric acid anti-secretory therapy for 4 to 8 weeks to promote initial healing and indefinitely to prevent recurrences of ulcer. The discovery of Helicobacter pylori in most patients with peptic ulcer disease has led to a change in this approach. Therapy designed to eradicate H pylori may facilitate ulcer healing with acid antisecretory agents and, more important, may greatly reduce the incidence of ulcer recurrence, obviating the need for maintenance antisecretory therapy. Regimens designed to eradicate H pylori are difficult to comply with, however, and are associated with adverse effects in some patients. In this article we review the diagnosis and treatment of H pylori infection in patients with peptic ulcer disease and make recommendations regarding the use of conventional ulcer therapies and therapies designed to eradicate H pylori.",
author = "M. Feldman and Peterson, {W. L.}",
year = "1993",
language = "English (US)",
volume = "159",
pages = "555--559",
journal = "Western Journal of Medicine",
issn = "0093-0415",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Helicobacter pylori and peptic ulcer disease

AU - Feldman, M.

AU - Peterson, W. L.

PY - 1993

Y1 - 1993

N2 - Medical therapy for duodenal or gastric ulcer disease has traditionally involved gastric acid anti-secretory therapy for 4 to 8 weeks to promote initial healing and indefinitely to prevent recurrences of ulcer. The discovery of Helicobacter pylori in most patients with peptic ulcer disease has led to a change in this approach. Therapy designed to eradicate H pylori may facilitate ulcer healing with acid antisecretory agents and, more important, may greatly reduce the incidence of ulcer recurrence, obviating the need for maintenance antisecretory therapy. Regimens designed to eradicate H pylori are difficult to comply with, however, and are associated with adverse effects in some patients. In this article we review the diagnosis and treatment of H pylori infection in patients with peptic ulcer disease and make recommendations regarding the use of conventional ulcer therapies and therapies designed to eradicate H pylori.

AB - Medical therapy for duodenal or gastric ulcer disease has traditionally involved gastric acid anti-secretory therapy for 4 to 8 weeks to promote initial healing and indefinitely to prevent recurrences of ulcer. The discovery of Helicobacter pylori in most patients with peptic ulcer disease has led to a change in this approach. Therapy designed to eradicate H pylori may facilitate ulcer healing with acid antisecretory agents and, more important, may greatly reduce the incidence of ulcer recurrence, obviating the need for maintenance antisecretory therapy. Regimens designed to eradicate H pylori are difficult to comply with, however, and are associated with adverse effects in some patients. In this article we review the diagnosis and treatment of H pylori infection in patients with peptic ulcer disease and make recommendations regarding the use of conventional ulcer therapies and therapies designed to eradicate H pylori.

UR - http://www.scopus.com/inward/record.url?scp=0027432088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027432088&partnerID=8YFLogxK

M3 - Article

VL - 159

SP - 555

EP - 559

JO - Western Journal of Medicine

JF - Western Journal of Medicine

SN - 0093-0415

IS - 5

ER -